This promotional material is intended for UK Healthcare Professionals (HCPs) experienced in the diagnosis and management of Parkinson’s disease only. Adverse event reporting can be found below
PRODUODOPA is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combination of Parkinson’s medicinal products have not given satisfactory results.1,2
Because levodopa may activate malignant melanoma, PRODUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.
PRODUODOPA is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combination of Parkinson’s medicinal products have not given satisfactory results.1,2
Because levodopa may activate malignant melanoma, PRODUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.
Some patients may not be suitable for PRODUODOPA. You are strongly advised to read the Prescribing information (PI), and Summary of Product Characteristics (SmPC) for Great Britain (GB) or Northern Ireland (NI) which can be found via the links above, to evaluate patient suitability for PRODUODOPA.
PRODUODOPA promotional training events
The AbbVie PRODUODOPA promotional training events aim to provide UK healthcare professionals information on the use of PRODUODOPA and the Vyafuser® pump. The two promotional training events in 2024 will be led by nurse educators.
PRODUODOPA promotional training event – May 2024
Date: 2nd May 2024
Time: 10:00-16:30
Location: Birmingham
Link will take you to a third party website, not controlled by AbbVie.
PRODUODOPA promotional training event – October 2024
Date: 9th October 2024
Time: 10:00-16:30
Location: London
Link will take you to a third party website, not controlled by AbbVie.
Please refer to the PRODUODOPA Summary of Product Characteristics (SmPC) for further information on adverse events, contraindications and special warnings and precautions for use.
References
- PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) GB Summary of Product Characteristics.
- PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) NI Summary of Product Characteristics.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on [email protected]
UK-PRODD-240046. Date of preparation: March 2024.
